Charles River Laboratories promotes Birgit Girshick to COO, adds Research Models & Services oversight
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Birgit Girshick promoted to Executive VP and COO, effective November 11, 2021.
She adds Research Models and Services to her existing responsibilities for Discovery, Safety Assessment, Biologics Solutions, and Cell & Gene Therapy CDMO.
Girshick has been with Charles River since 1989, leading strategic initiatives and integrating acquisitions like Cognate BioServices and Vigene Biosciences.
James C. Foster remains Chairman, President and CEO; his employment agreement was extended to February 2026.
CRL ·
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Effective
2021-11-11
Filed
November 12, 2021, 6:59 PM ET
On November 11, 2021, Charles River Laboratories International, Inc. (the "Company") announced that Ms. Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment and Biologics Testing Solutions, will become Chief Operating Officer of the Company, effective immediately, and will add Research Models and Services to her responsibilities.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Birgit Girshick was appointed as Chief Operating Officer at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
Action
appointed
Role
Chief Operating Officer
Exact text from the filing
On November 11, 2021, Charles River Laboratories International, Inc. (the "Company") announced that Ms. Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment and Biologics Testing Solutions, will become Chief Operating Officer of the Company, effective immediately, and will add Research Models and Services to her responsibilities.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.